Back to top

Image: Bigstock

Novo-Nordisk A/S

Read MoreHide Full Article

Novo Nordisk’s earnings and sales were below the Zacks Consensus Estimate in the fourth quarter of 2016.  The company faces generic threat for several of its products as well as patent expiration issues. We are also concerned about the company’s insulin product prices that are either subsidized or subject to price control.  Growth in 2017 is expected to negatively impacted due to the launch of a generic version of Vagifem in the U.S. Shares of Novo Nordisk have significantly underperformed the Large Cap Pharmaceuticals industry in 2016.  However, strong performance of drugs like Victoza, Tresiba, Saxenda, Xultophy among others continue to bolster performance. The company also submitted a new drug application (NDA) to the Japanese Ministry of Health, Labour and Welfare for its key pipeline candidate semaglutide (once-weekly), for the treatment of adults with type II diabetes.


In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Novo Nordisk AS (NVO) - free report >>